Announcement PDF Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public. Introduced 30/09/01 Amended 01/01/11 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Part 1 - Change of director's relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part. Appendix 3Y Change of Director's Interest Notice Name of entity Paradigm Biopharmaceuticals Limited ABN 94 169 346 963 Name of director Paul Rennie Date of last notice 23 February 2026 Direct or indirect interest (1) Direct (2) Indirect (3) Indirect (4) Indirect (5) Indirect (6) Direct (7) Indirect Nature of indirect interest (including registered holder) (1) N/A (2) SMSF (3) FT (4) SMSF (5) SMSF (6) N/A (7) SMSF Date of change (1) 02 June 2026 (2) 02 June 2026 (7) 02 June 2026 + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director's Interest Notice No. of securities held prior to change (1) 200,000 - FULLY PAID ORDINARY SHARES (2) 10,767,843 - FULLY PAID ORDINARY SHARES (3) 600,000 - FULLY PAID ORDINARY SHARES (4.1) 1,700,000 - PERFORMANCE RIGHTS EXP 20/12/2027 (4.2) 1,500,000 - PERFORMANCE RIGHTS EXP 17/02/2029 (5) 76,633 - UNLISTED PIGGYBACK OPTS @ $1 EXP 11/02/2028 (6) 8,545,848 - FULLY PAID ORDINARY SHARES (7) 766,324 - FULLY PAID ORDINARY SHARES Class (1) FULLY PAID ORDINARY SHARES (2) FULLY PAID ORDINARY SHARES (3) FULLY PAID ORDINARY SHARES (4.1) PERFORMANCE RIGHTS EXP 20/12/2027 (4.2) PERFORMANCE RIGHTS EXP 17/02/2029 (5) UNLISTED PIGGYBACK OPTS @ $1 EXP 11/02/2028 (6) FULLY PAID ORDINARY SHARES (7) FULLY PAID ORDINARY SHARES Number acquired (1) 176,470 - FULLY PAID ORDINARY SHARES (2) 176,470 - FULLY PAID ORDINARY SHARES (7) 176,470 - FULLY PAID ORDINARY SHARES Number disposed NIL Value/Consideration (1) $30,000 - FULLY PAID ORDINARY SHARES (2) $30,000 - FULLY PAID ORDINARY SHARES (7) $30,000 - FULLY PAID ORDINARY SHARES No. of securities held after change (1) 376,470 - FULLY PAID ORDINARY SHARES (2) 10,944,313 - FULLY PAID ORDINARY SHARES (3) 600,000 - FULLY PAID ORDINARY SHARES (4.1) 1,700,000 - PERFORMANCE RIGHTS EXP 20/12/2027 (4.2) 1,500,000 - PERFORMANCE RIGHTS EXP 17/02/2029 (5) 76,633 - UNLISTED PIGGYBACK OPTS @ $1 EXP 11/02/2028 (6) 8,545,848 - FULLY PAID ORDINARY SHARES (7) 942,794 - FULLY PAID ORDINARY SHARES + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 2 Part 2 - Change of director's relevant interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part. Part 3 - +Closed period Appendix 3Y Change of Director's Interest Notice Nature of change (1) Share purchase plan acceptance (2) Share purchase plan acceptance (7) Share purchase plan acceptance Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change N/A Interest acquired N/A Interest disposed N/A Value/Consideration N/A Interest after change N/A Were the interests in the securities or contracts detailed above traded during a + closed period where prior written clearance was required? NO If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3